Entries by Max

UPDATE: AO-252 Demonstrates 80% Clinical Benefit Rate as Development Shifts to Expansion Phase

/in , , , /by

AO-252, a first-in-class TACC3 inhibitor, continues to show early clinical promise in advanced solid tumours, with recent updates highlighting both improved efficacy through optimized dosing and a new formulation designed to enhance drug exposure. Interim data from an ongoing Phase 1/2 trial demonstrated a clear dosing-dependent effect. Transitioning from once-daily (QD) to twice-daily (BID) administration […]

Soon to Start Phase 1/2 Trial: CRISPR-Edited Tregs Enter the Clinic for Solid Tumors

/in , , , /by

CRG-150, a CRISPR-edited regulatory T cell therapy has entered first-in-human testing for solid tumors, marking an unusual and potentially important step in oncology. The program is aimed at metastatic breast and prostate cancers, two settings where treatment options remain limited once disease becomes advanced. What makes this approach different is the cell type being used. […]

Newsletter 27/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Another week, another batch of research. It’s a bit slower now, I suppose researchers need holidays too, but here we go. Stay strong and fight on! And a Happy 4th of July to our US subscribers! As usual, we […]

PARP Inhibition Combined with Targeted T-Cell Activation Drives Polyclonal Antitumor Immunity in mCRPC

/in , /by

A novel therapeutic strategy combining PARP inhibition with selective T-cell receptor β chain activation is showing promising potential to overcome immune resistance in metastatic castration-resistant prostate cancer (mCRPC). This approach pairs olaparib, a well-established PARP inhibitor, with a bifunctional T-cell agonist (STAR0602) designed to selectively expand specific T-cell subsets through targeted delivery of interleukin-2. Prostate […]

GPS-ProMPT: Molecular Profiling Identifies Overtreated Prostate Cancer Subgroup

/in /by

A retrospective analysis from the Oxford GPS-ProMPT study provides further evidence that genomic profiling can reveal which prostate cancers are truly aggressive and which are not, even when clinical features suggest otherwise. The study evaluated the 17-gene Genomic Prostate Score (GPS mdx) in 409 patients managed with active surveillance, radical prostatectomy, or radiotherapy with androgen […]

RIPCORD Phase 1 Trial: Interim PSMA PET–Guided Adaptive Radiotherapy in Metastatic Castration-Sensitive Prostate Cancer

/in , , /by

RIPCORD is a UT Southwestern phase 1 trial testing a simple but important idea: can PSMA PET be used during treatment to decide how much metastasis-directed radiotherapy a patient actually needs? It focuses on men with poly-metastatic castration-sensitive prostate cancer and uses interim 68Ga-PSMA-11 PET to adapt stereotactic ablative radiotherapy (SABR) rather than giving every […]

Phase 1 Trial: 177Lu-PSMA-617 Plus Darolutamide in High-Risk Localized Prostate Cancer

/in , , /by

A new trial phase 1 trial is investigating the combination of 177Lu-PSMA-617 (Pluvicto) with darolutamide in high-risk localized prostate cancer. Both agents are already established in prostate cancer care, but using them together before surgery is a novel way to intensify treatment in patients whose disease is still potentially curable. Its main idea is simple: […]

GRPR-Targeted Radioligand Therapy in Prostate Cancer: The A9-0631 and A9-0642 Trial

/in , , , , /by

A new first-in-human study is testing whether GRPR-targeted radiopharmaceuticals can extend precision oncology beyond the PSMA and SSTR frameworks. The trial combines two therapeutic agents, 177Lu-A9-0631 and 225Ac-A9-0642, with GRPR imaging using 68Ga-A9-6217 or low-dose 177Lu-A9-0631 in patients with GRPR-positive solid tumors. GRPR, or gastrin-releasing peptide receptor, is an appealing target because it is overexpressed […]

ARTO Trial Final Results: Long-Term Survival Benefit of SBRT Added to Abiraterone in Oligometastatic mCRPC

/in , , /by

The phase 2 ARTO trial findings, published on The Lancet, provides stronger evidence that metastasis-directed SBRT can improve outcomes in oligometastatic castration-resistant prostate cancer. In this randomized study, 157 patients were enrolled across 16 academic and community centers in Italy and assigned 1:1 to abiraterone plus ADT with or without SBRT to all visible metastatic […]